Cargando…

ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum

Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complication of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of EN...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Stephen L., Balagon, Marivic, Darlong, Joydeepa, Doni, Shimelis N., Hagge, Deanna A., Halwai, Vikas, John, Annamma, Lambert, Saba M., Maghanoy, Armi, Nery, Jose A. C., Neupane, Kapil D., Nicholls, Peter G., Pai, Vivek V., Parajuli, Pawan, Sales, Anna M., Sarno, Euzenir, Shah, Mahesh, Tsegaye, Digafe, Lockwood, Diana N. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564249/
https://www.ncbi.nlm.nih.gov/pubmed/26351858
http://dx.doi.org/10.1371/journal.pntd.0004065
_version_ 1782389405500047360
author Walker, Stephen L.
Balagon, Marivic
Darlong, Joydeepa
Doni, Shimelis N.
Hagge, Deanna A.
Halwai, Vikas
John, Annamma
Lambert, Saba M.
Maghanoy, Armi
Nery, Jose A. C.
Neupane, Kapil D.
Nicholls, Peter G.
Pai, Vivek V.
Parajuli, Pawan
Sales, Anna M.
Sarno, Euzenir
Shah, Mahesh
Tsegaye, Digafe
Lockwood, Diana N. J.
author_facet Walker, Stephen L.
Balagon, Marivic
Darlong, Joydeepa
Doni, Shimelis N.
Hagge, Deanna A.
Halwai, Vikas
John, Annamma
Lambert, Saba M.
Maghanoy, Armi
Nery, Jose A. C.
Neupane, Kapil D.
Nicholls, Peter G.
Pai, Vivek V.
Parajuli, Pawan
Sales, Anna M.
Sarno, Euzenir
Shah, Mahesh
Tsegaye, Digafe
Lockwood, Diana N. J.
author_sort Walker, Stephen L.
collection PubMed
description Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complication of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of ENL requires immunosuppression, which is often required for prolonged periods of time and may lead to serious adverse effects. ENL and its treatment is associated with increased mortality and economic hardship. Improved, evidence-based treatments for ENL are needed; however, defining the severity of ENL and outcome measures for treatment studies is difficult because of the multiple organ systems involved. A cross-sectional study was performed, by the members of the Erythema Nodosum Leprosum International STudy (ENLIST) Group, of patients with ENL attending seven leprosy referral centres in Brazil, Ethiopia, India, Nepal, the Philippines and the United Kingdom. We systematically documented the clinical features and type of ENL, its severity and the drugs used to treat it. Patients with chronic ENL were more likely to be assessed as having severe ENL. Pain, the most frequent symptom, assessed using a semi-quantitative scale was significantly worse in individuals with “severe” ENL. Our findings will determine the items to be included in a severity scale of ENL which we are developing and validating. The study also provides data on the clinical features of ENL, which can be incorporated into a definition of ENL and used for outcome measures in treatment studies.
format Online
Article
Text
id pubmed-4564249
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45642492015-09-17 ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum Walker, Stephen L. Balagon, Marivic Darlong, Joydeepa Doni, Shimelis N. Hagge, Deanna A. Halwai, Vikas John, Annamma Lambert, Saba M. Maghanoy, Armi Nery, Jose A. C. Neupane, Kapil D. Nicholls, Peter G. Pai, Vivek V. Parajuli, Pawan Sales, Anna M. Sarno, Euzenir Shah, Mahesh Tsegaye, Digafe Lockwood, Diana N. J. PLoS Negl Trop Dis Research Article Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complication of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of ENL requires immunosuppression, which is often required for prolonged periods of time and may lead to serious adverse effects. ENL and its treatment is associated with increased mortality and economic hardship. Improved, evidence-based treatments for ENL are needed; however, defining the severity of ENL and outcome measures for treatment studies is difficult because of the multiple organ systems involved. A cross-sectional study was performed, by the members of the Erythema Nodosum Leprosum International STudy (ENLIST) Group, of patients with ENL attending seven leprosy referral centres in Brazil, Ethiopia, India, Nepal, the Philippines and the United Kingdom. We systematically documented the clinical features and type of ENL, its severity and the drugs used to treat it. Patients with chronic ENL were more likely to be assessed as having severe ENL. Pain, the most frequent symptom, assessed using a semi-quantitative scale was significantly worse in individuals with “severe” ENL. Our findings will determine the items to be included in a severity scale of ENL which we are developing and validating. The study also provides data on the clinical features of ENL, which can be incorporated into a definition of ENL and used for outcome measures in treatment studies. Public Library of Science 2015-09-09 /pmc/articles/PMC4564249/ /pubmed/26351858 http://dx.doi.org/10.1371/journal.pntd.0004065 Text en © 2015 Walker et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Walker, Stephen L.
Balagon, Marivic
Darlong, Joydeepa
Doni, Shimelis N.
Hagge, Deanna A.
Halwai, Vikas
John, Annamma
Lambert, Saba M.
Maghanoy, Armi
Nery, Jose A. C.
Neupane, Kapil D.
Nicholls, Peter G.
Pai, Vivek V.
Parajuli, Pawan
Sales, Anna M.
Sarno, Euzenir
Shah, Mahesh
Tsegaye, Digafe
Lockwood, Diana N. J.
ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
title ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
title_full ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
title_fullStr ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
title_full_unstemmed ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
title_short ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
title_sort enlist 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564249/
https://www.ncbi.nlm.nih.gov/pubmed/26351858
http://dx.doi.org/10.1371/journal.pntd.0004065
work_keys_str_mv AT walkerstephenl enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT balagonmarivic enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT darlongjoydeepa enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT donishimelisn enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT haggedeannaa enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT halwaivikas enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT johnannamma enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT lambertsabam enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT maghanoyarmi enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT neryjoseac enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT neupanekapild enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT nichollspeterg enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT paivivekv enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT parajulipawan enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT salesannam enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT sarnoeuzenir enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT shahmahesh enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT tsegayedigafe enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT lockwooddiananj enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum
AT enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum